ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused
on the prevention and treatment of serious infectious diseases,
announced today that Jeffrey Riley,
CEO, will present at the 2nd Annual Marcum LLP MicroCap
Conference on Thursday, May 30, 2013
in New York City at the Grand
Hyatt Hotel. Mr. Riley is scheduled to present at 10:00 a.m. (Eastern Time).
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the web at
http://wsw.com/webcast/marcum/syn/. After the presentation,
a replay will be archived and accessible for 30 days at the same
website.
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to
participate in one-on-one meetings with investors and analysts who
are registered to attend the conference. Please contact the Marcum
conference representative Taline
Chalian at taline.chalian@marcumllp.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of biologics for the prevention
and treatment of serious infectious diseases. The Company is
developing an oral enzyme for the prevention of C. difficile
infections, and a series of monoclonal antibody therapies for the
treatment of Pertussis and Acinetobacter infections. In
addition, the Company is developing a drug candidate for the
treatment of relapsing-remitting multiple sclerosis and cognitive
dysfunction in multiple sclerosis. For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.
SOURCE Synthetic Biologics, Inc.